menu
menu
Lung Cancer
Biomarker testing has become central to the diagnosis and management of non-small cell lung cancer, yet the rapid expansion of actionable targets and testing technologies has introduced new challenges for pathology and laboratory teams. In this episode, expert panelists reflect on how NSCLC biomarker testing has evolved over the past decade, driven by advances in targeted therapies, next-generation sequencing, and professional practice guidelines.
The discussion focuses on the clinical relevance of emerging biomarkers, the rationale behind broad molecular profiling, and real-world decision-making around testing strategies and platform selection.
During this recorded 2022 ASCP Annual Meeting session, multidisciplinary faculty discuss the science and latest evidence on emerging biomarkers, resistance mutations, immuno-oncology (I-O) resistance mechanisms, and I-O treatment options (e.g., combination therapy involving CTLA-4 inhibitors) in metastatic NSCLC. Participants will learn how to integrate next generation sequencing (NGS) into their biomarker testing workflows and optimize its use for patients. Finally, faculty share best practices in biomarker testing, reporting, and communication to help pathologists and laboratory professionals guide medical oncologists and other team members in the appropriate diagnosis, testing, and treatment for patients.